The amount of revenue arising from the sale of goods. [Refer: Revenue]

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IAS
-Number 1
-IssueDate 2023-01-01
-Paragraph 112
-Subparagraph c
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_112_c&doctype=Standard
-URIDate 2023-03-23

+ Details

Name:	ifrs-full_RevenueFromSaleOfGoods
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Disclosure of detailed information about Principal Alliances [Line Items]

+ References

No definition available.

+ Details

Name:	sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems
Namespace Prefix:	sny_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Number Of Agreements Signed

+ References

No definition available.

+ Details

Name:	sny_NumberOfAgreementsSigned
Namespace Prefix:	sny_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number Of Payments

+ References

No definition available.

+ Details

Name:	sny_NumberOfPayments
Namespace Prefix:	sny_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Payment Related To Attainment Of Goal

+ References

No definition available.

+ Details

Name:	sny_PaymentRelatedToAttainmentOfGoal
Namespace Prefix:	sny_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Percentage of cumulative development costs reimbursed.

+ References

No definition available.

+ Details

Name:	sny_PercentageOfCumulativeDevelopmentCostsReimbursed
Namespace Prefix:	sny_
Data Type:	dtr-types1:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage Of Losses Arising From Commercial Operations

+ References

No definition available.

+ Details

Name:	sny_PercentageOfLossesArisingFromCommercialOperations
Namespace Prefix:	sny_
Data Type:	dtr-types1:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage of profit share on counter parties profit.

+ References

No definition available.

+ Details

Name:	sny_PercentageOfProfitShareOnCounterpartiesProfit
Namespace Prefix:	sny_
Data Type:	dtr-types1:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage of profits and losses arising from commercial operations.

+ References

No definition available.

+ Details

Name:	sny_PercentageOfProfitsAndLossesArisingFromCommercialOperations
Namespace Prefix:	sny_
Data Type:	dtr-types1:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage Of Profits Arising From Commercial Operations

+ References

No definition available.

+ Details

Name:	sny_PercentageOfProfitsArisingFromCommercialOperations
Namespace Prefix:	sny_
Data Type:	dtr-types1:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage Of Second Part Of Development Costs Funded

+ References

No definition available.

+ Details

Name:	sny_PercentageOfSecondPartOfDevelopmentCostsFunded
Namespace Prefix:	sny_
Data Type:	dtr-types1:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage of second part of development costs funded by other party.

+ References

No definition available.

+ Details

Name:	sny_PercentageOfSecondPartOfDevelopmentCostsFundedByOtherParty
Namespace Prefix:	sny_
Data Type:	dtr-types1:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Period Before Launch Date During Which Commercial Expenses Of Antibodies Co-Developed Under License Agreement Are Shared

+ References

No definition available.

+ Details

Name:	sny_PeriodBeforeLaunchDateDuringWhichCommercialExpensesOfAntibodiesCoDevelopedUnderLicenseAgreementAreShared
Namespace Prefix:	sny_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Royalty Expense, Percentage

+ References

No definition available.

+ Details

Name:	sny_RoyaltyExpensePercentage
Namespace Prefix:	sny_
Data Type:	dtr-types1:percentItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	ifrs-full_GeographicalAreasAxis=country_US
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_CounterpartiesAxis=sny_RegeneronPharmaceuticalsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	sny_PrincipalAlliancesAxis=sny_AntibodiesCollaborationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	sny_TypesOfAgreementAxis=sny_SalesOfAntibodiesFirstAchievementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=sny_AntibodiesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	sny_TypesOfAgreementAxis=sny_SalesOfAntibodiesSecondAchievementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	sny_TypesOfAgreementAxis=sny_PriorAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	sny_TypesOfAgreementAxis=sny_NewAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	sny_TypesOfAgreementAxis=sny_SalesOfAntibodiesThirdAchievementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_GeographicalAreasAxis=sny_OutsideUnitedStatesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	sny_PrincipalAlliancesAxis=sny_ImmunoOncologyCollaborationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Principal alliances - Collaboration agreements on human therapeutic antibodies (Details) € in Millions, $ in Millions			1 Months Ended	3 Months Ended	9 Months Ended	12 Months Ended
	Apr. 01, 2020	Jul. 01, 2015 agreement	Nov. 30, 2007 agreement	Mar. 31, 2022	Dec. 31, 2022 Rate	Dec. 31, 2023 EUR (€) Rate	Dec. 31, 2023 USD ($) Rate	Dec. 31, 2022 EUR (€) bond	Dec. 31, 2022 USD ($) bond	Dec. 31, 2021 EUR (€)	Dec. 31, 2015
Disclosure of detailed information about Principal Alliances [Line Items]
Net sales \| €						€ 43,070		€ 42,997		€ 37,761
US
Disclosure of detailed information about Principal Alliances [Line Items]
Net sales \| €						€ 18,512		€ 18,275		€ 14,385
Regeneron Pharmaceuticals, INC \| Antibodies Collaboration agreement
Disclosure of detailed information about Principal Alliances [Line Items]
Number of agreements signed \| agreement			2
Phase III costs, responsibility percentage						80.00%	80.00%
Phase III costs, responsibility percentage for Regeneron						20.00%	20.00%
Maximum additional profit-share, in percentage of Regeneron's quarterly profit (in percent)				10.00%	20.00%
Percentage of cumulative development costs reimbursed						50.00%	50.00%	50.00%	50.00%
Period before scheduled launch date						24 months	24 months
Number of payments \| bond								2	2
Regeneron Pharmaceuticals, INC \| Antibodies Collaboration agreement \| Sales of antibodies, first achievement
Disclosure of detailed information about Principal Alliances [Line Items]
Payment related to attainment of goal									$ 50
Regeneron Pharmaceuticals, INC \| Antibodies Collaboration agreement \| Sales of antibodies, first achievement \| Antibodies
Disclosure of detailed information about Principal Alliances [Line Items]
Net sales									2,000
Regeneron Pharmaceuticals, INC \| Antibodies Collaboration agreement \| Sales of antibodies, second achievement
Disclosure of detailed information about Principal Alliances [Line Items]
Payment related to attainment of goal									50
Regeneron Pharmaceuticals, INC \| Antibodies Collaboration agreement \| Sales of antibodies, second achievement \| Antibodies
Disclosure of detailed information about Principal Alliances [Line Items]
Net sales									$ 2,500
Regeneron Pharmaceuticals, INC \| Antibodies Collaboration agreement \| Prior agreement
Disclosure of detailed information about Principal Alliances [Line Items]
Maximum additional profit-share, in percentage of Regeneron's quarterly profit (in percent) \| Rate					10.00%	10.00%	10.00%
Regeneron Pharmaceuticals, INC \| Antibodies Collaboration agreement \| New agreement
Disclosure of detailed information about Principal Alliances [Line Items]
Maximum additional profit-share, in percentage of Regeneron's quarterly profit (in percent) \| Rate						20.00%	20.00%
Regeneron Pharmaceuticals, INC \| Antibodies Collaboration agreement \| Sales Of Antibodies, Third Achievement
Disclosure of detailed information about Principal Alliances [Line Items]
Payment related to attainment of goal							$ 50
Regeneron Pharmaceuticals, INC \| Antibodies Collaboration agreement \| Sales Of Antibodies, Third Achievement \| Antibodies
Disclosure of detailed information about Principal Alliances [Line Items]
Net sales							$ 3,000
Regeneron Pharmaceuticals, INC \| Antibodies Collaboration agreement \| US
Disclosure of detailed information about Principal Alliances [Line Items]
Percentage of profits and losses arising from commercial operations						50.00%	50.00%
Regeneron Pharmaceuticals, INC \| Antibodies Collaboration agreement \| Outside the United States
Disclosure of detailed information about Principal Alliances [Line Items]
Percentage of losses arising from commercial operations						55.00%	55.00%
Royalty expense, percentage (percentage)	5.00%
Regeneron Pharmaceuticals, INC \| Antibodies Collaboration agreement \| Outside the United States \| Bottom of range
Disclosure of detailed information about Principal Alliances [Line Items]
Percentage of profits arising from commercial operations						55.00%	55.00%
Regeneron Pharmaceuticals, INC \| Antibodies Collaboration agreement \| Outside the United States \| Top of range
Disclosure of detailed information about Principal Alliances [Line Items]
Percentage of profits arising from commercial operations						65.00%	65.00%
Regeneron Pharmaceuticals, INC \| Immuno-oncology collaboration agreement
Disclosure of detailed information about Principal Alliances [Line Items]
Number of agreements signed \| agreement		2
Maximum additional profit-share, in percentage of Regeneron's quarterly profit (in percent)											10.00%
Percentage of cumulative development costs reimbursed											50.00%